See more : Borqs Technologies, Inc. (BRQSF) Income Statement Analysis – Financial Results
Complete financial analysis of Pliant Therapeutics, Inc. (PLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pliant Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Cryptology Asset Group plc (CAGPF) Income Statement Analysis – Financial Results
- Sunex S.A. (SNX.WA) Income Statement Analysis – Financial Results
- Herborium Group, Inc. (HBRM) Income Statement Analysis – Financial Results
- Vita Group Limited (VTG.AX) Income Statement Analysis – Financial Results
- Magnificent Hotel Investments Limited (0201.HK) Income Statement Analysis – Financial Results
Pliant Therapeutics, Inc. (PLRX)
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.58M | 9.69M | 7.57M | 41.82M | 57.05M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 3.68M | 3.20M | 0.00 | 0.00 | 666.00K | 0.00 |
| Gross Profit | 1.58M | 6.00M | 4.37M | 41.82M | 57.05M | -666.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 61.99% | 57.69% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 127.80M | 96.94M | 77.55M | 66.19M | 47.35M | 24.42M | 14.53M |
| General & Administrative | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Other Expenses | 0.00 | 0.00 | -77.55M | -366.00K | -216.00K | -49.00K | 0.00 |
| Operating Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Cost & Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Interest Income | 24.08M | 4.67M | 272.00K | 478.00K | 816.00K | 688.00K | 16.00K |
| Interest Expense | 1.27M | 791.00K | 272.00K | 366.00K | 216.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.84M | 3.68M | 3.20M | 1.31M | 1.11M | 666.00K | 292.00K |
| EBITDA | -158.23M | -118.85M | -95.73M | -40.34M | -118.00K | -30.25M | -18.06M |
| EBITDA Ratio | -10,014.43% | -1,265.15% | -263.95% | -99.59% | -0.21% | 0.00% | 0.00% |
| Operating Income | -184.15M | -127.20M | -19.99M | -41.65M | -1.23M | -30.92M | -18.35M |
| Operating Income Ratio | -11,654.75% | -1,313.37% | -263.95% | -99.59% | -2.16% | 0.00% | 0.00% |
| Total Other Income/Expenses | 22.81M | 3.88M | 272.00K | 112.00K | 600.00K | 639.00K | 16.00K |
| Income Before Tax | -161.34M | -123.32M | -19.71M | -41.53M | -631.00K | -30.28M | -18.33M |
| Income Before Tax Ratio | -10,211.14% | -1,273.32% | -260.35% | -99.32% | -1.11% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.82M | -1.81M | -1.79M | -816.00K | 639.00K | 2.29M |
| Net Income | -161.34M | -121.50M | -17.91M | -39.75M | 185.00K | -30.28M | -20.62M |
| Net Income Ratio | -10,211.14% | -1,254.50% | -236.49% | -95.05% | 0.32% | 0.00% | 0.00% |
| EPS | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| EPS Diluted | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| Weighted Avg Shares Out | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
| Weighted Avg Shares Out (Dil) | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
7 Cheap Biotech Stocks to Buy Now
2022 Roundtable: Our Favorite Picks Right Now
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
What's Going On With Pliant Therapeutics Stock?
Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?
After-Hours Alert: Why Pliant Therapeutics Stock Is Moving
Why Pliant Therapeutics Stock Is Crushing It Today
Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?
Pliant Therapeutics (PLRX) Stock: Why It Skyrocketed Over 60% Today
Source: https://incomestatements.info
Category: Stock Reports